Search

Your search keyword '"Dhooria, Sahajal"' showing total 1,274 results
Start Over Author "Dhooria, Sahajal"
1,274 results on '"Dhooria, Sahajal"'

4. Indian Rheumatology Association guidelines for the management of ANCA associated vasculitis

Author

Dhooria, Aadhaar, Naidu, G.S.R.S.N.K., Misra, Durga Prasanna, Pinto, Benzeeta, Adarsh, M.B., Jha, Saket, Kumar, Rajiv Ranjan, Chattopadhyay, Arghya, Sharma, Vikas, Mishra, Debashish, Acharya, Nupoor, Mittal, Sakshi, Jain, Siddharth, Samanta, Joydeep, Kavadichanda, Chengappa, Dhooria, Sahajal, Ramachandran, Raja, Jois, Ramesh, Sharma, Banwari, Balakrishnan, Canchi, Shobha, Vineeta, Kumar, Uma, Agarwal, Vikas, Dharmanand, B.G., Handa, Rohini, and Sharma, Aman

Published
2024
Full Text
View/download PDF

20. Five principles and protocols for the clinician based on the 2021 ERS and BTS statements for treating sarcoidosis.

Author

Dhooria, Sahajal

Subjects
*INTERSTITIAL lung diseases, *SARCOIDOSIS, *METHOTREXATE, *PREDNISONE, *AZATHIOPRINE, *QUALITY of life
Abstract

The European Respiratory Society (ERS) and the British Thoracic Society (BTS) have recently published their statements on the treatment of sarcoidosis. There are five key questions in sarcoidosis treatment that need to be addressed: when to treat, how to initiate treatment, how long to treat, when and how to change treatment, and how to treat relapses. Herein, we describe the principles and protocols to answer these questions based on the ERS and BTS statements and other expert reviews. Pulmonary or extrapulmonary sarcoidosis should be treated with anti-inflammatory therapy if it significantly impairs the quality of life (QoL), causes significant organ dysfunction, or threatens to cause organ damage, disability, or death. If treatment is initiated for improving the QoL alone, low-dose (10 mg/day) prednisone is a good initial treatment that can be tapered and stopped over 3 months. Disease that causes significant organ dysfunction needs to be treated with medium-dose glucocorticoids (initial daily dose, 20 mg of prednisone equivalent) tapered over a minimum duration of 6 months. Worsening of disease while tapering treatment indicates that longer (9-24 months) treatment may be necessary. If a daily prednisone dose of >10 mg is required for >6 months to maintain remission, it is best to use a second-line drug such as methotrexate or azathioprine. Anti-tumor necrosis factor agents, such as infliximab or adalimumab, may be used to treat inflammatory disease that persists on combination treatment with glucocorticoids and a second-line agent. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Bronchiectasis Severity Index and FACED scores in patients with allergic bronchopulmonary aspergillosis complicating asthma: do they correlate with immunological severity or high-attenuation mucus?

Author

Phadnis, Shruti, Muthu, Valliappan, Sehgal, Inderpaul S., Prasad, Kuruswamy T., Dhooria, Sahajal, Aggarwal, Ashutosh N., and Agarwal, Ritesh

Subjects
PULMONARY aspergillosis, BRONCHIECTASIS, MYCOSES, MUCUS, QUALITY of life
Abstract

Background: The utility of two disease-severity indices, namely bronchiectasis severity index (BSI) and FACED score in allergic bronchopulmonary aspergillosis (ABPA) remains unknown. Objective: To correlate the BSI and FACED scores with immunological parameters (serum IgE [total and A. fumigatus-specific], A. fumigatus-specific IgG, blood eosinophil count), and high-attenuation mucus on chest computed tomography in ABPA. The secondary objectives were to evaluate the correlation between BSI and FACED scores and correlate the BSI/FACED scores with the bronchiectasis health questionnaire (BHQ) and Saint George's Respiratory Questionnaire (SGRQ). Methods: We included treatment-naïve ABPA subjects with bronchiectasis in a prospective observational study. We computed the BSI and FACED scores for each subject before initiating treatment. The subjects also completed two quality-of-life questionnaires (BHQ and SGRQ). Results: We included 91 subjects. The mean (standard deviation) BSI and FACED scores were 3.43 (3.39) and 1.43 (1.27). We found no correlation between BSI or FACED with any immunological parameter or high-attenuation mucus. There was a strong correlation between BSI and FACED scores (r = 0.76, p < 0.001). We found a weak correlation between BSI and BHQ/SGRQ and FACED and SGRQ. Conclusion: We found no correlation between BSI and FACED with immunological parameters in ABPA. However, we found a significant correlation between BSI and FACED and a weak correlation between SGRQ and BHQ. ABPA likely requires a separate disease-severity scoring system. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Airway Foreign Bodies: Rigid vs Flexible Approach

Author

Sehgal, Inderpaul Singh, Dhooria, Sahajal, Goyal, Rajiv, Agarwal, Ritesh, Rounds, Sharon I. S., Series Editor, Dixon, Anne, Series Editor, Schnapp, Lynn M., Series Editor, Turner, Jr., J. Francis, editor, Jain, Prasoon, editor, Yasufuku, Kazuhiro, editor, and Mehta, Atul C., editor

Published
2021
Full Text
View/download PDF

25. Bronchial Valves for Persistent Air Leak

Author

Damaraju, Vikram, primary, Sehgal, Inderpaul Singh, additional, Muthu, Valliappan, additional, Prasad, Kuruswamy Thurai, additional, Dhooria, Sahajal, additional, Aggarwal, Ashutosh Nath, additional, and Agarwal, Ritesh, additional

Published
2024
Full Text
View/download PDF

27. Pleural effusion guidelines from ICS and NCCP Section 1: Basic principles, laboratory tests and pleural procedures

Author

Christopher, Devasahayam J., primary, Gupta, Richa, additional, Thangakunam, Balamugesh, additional, Daniel, Jefferson, additional, Jindal, Surinder K., additional, Kant, Surya, additional, Chhajed, Prashant N., additional, Gupta, K B, additional, Dhooria, Sahajal, additional, Chaudhri, Sudhir, additional, Chaudhry, Dhruva, additional, Patel, Dharmesh, additional, Mehta, Ravindra, additional, Chawla, Rakesh K., additional, Srinivasan, Arjun, additional, Kumar, Arvind, additional, Bal, Shakti K., additional, James, Prince, additional, Roger, Jebin S, additional, Nair, Avinash A., additional, Katiyar, S K, additional, Agarwal, Ritesh, additional, Dhar, Raja, additional, Aggarwal, Ashutosh N., additional, Samaria, J K, additional, Behera, Digambar, additional, Madan, Karan, additional, Singh, Raj B, additional, Luhadia, S K, additional, Sarangdhar, Nikhil, additional, Souza, George D’, additional, Nene, Amita, additional, Paul, Akhil, additional, Varghese, Vimi, additional, Rajagopal, T V, additional, Arun, M, additional, Nair, Shraddha, additional, Roy, Dhivya A, additional, Williams, Benjamin E., additional, Christopher, Shona A., additional, Subodh, Dhanawade V., additional, Sinha, Nishant, additional, Isaac, Barney, additional, Oliver, Ashwin A, additional, Priya, N, additional, Deva, Jedidiah, additional, Chandy, Sujith T., additional, and Kurien, Richu Bob, additional

Published
2024
Full Text
View/download PDF

36. The minimal important difference of one-minute-sit-to-stand test in subjects with chronic pulmonary aspergillosis.

Author

Sehgal, Inderpaul Singh, Dhooria, Sahajal, Muthu, Valliappan, Prasad, Kuruswamy Thurai, Soundappan, Kathirvel, Aggarwal, Ashutosh Nath, Chakrabarti, Arunaloke, Rudramurthy, Shivaprakash Mandya, and Agarwal, Ritesh

Subjects
*PULMONARY aspergillosis, *VISUAL analog scale
Abstract

Background and objective: There is a need for simple functional test to assess treatment response in chronic pulmonary aspergillosis (CPA) in resource-constrained settings. The one-minute-sit-to-stand test (1-min-STS) is one such test. However, the minimal important difference (MID) for 1-min-STS in subjects with CPA remains unknown. Herein, we estimate the MID for 1-min-STS for CPA subjects. Materials and Methods: We retrospectively reviewed the clinical details of CPA subjects treated with oral azoles for 6 months. We included only subjects who completed the 1-min-STS test at baseline and 6 months. We used the change in VAS (visual analogue scale, for overall improvement) as an external anchor. We used the anchor and the distribution (standard deviation-based) methods to determine the MID estimates. We used the anchor-based method only if there was correlation of 0.3 with the 1-min-STS test. Results: One hundred-eight subjects completed the 1-min-STS test at baseline and 6 months. We did not find significant correlation between the change in VAS for overall improvement (r² = 0.024, P value = 0.809) and the 1-min-STS test. The MID for the 1-min-STS test was 2 repetitions (range, 1.5--2.8 repetitions). Conclusion: The MID for the 1-min-STS test in subjects with CPA was 2 repetitions. Future studies using a global rating of change scale as an anchor must confirm our findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Aspergillus sensitization in non-smokers versus smokers with chronic obstructive pulmonary disease.

Author

Muthu, Valliappan, Kumar, Ravinish, Prasad, Kuruswamy Thurai, Sehgal, Inderpaul Singh, Dhooria, Sahajal, Soundappan, Kathirvel, Rudramurthy, Shivaprakash Mandya, Chakrabarti, Arunaloke, Aggarwal, Ashutosh N., and Agarwal, Ritesh

Subjects
CHRONIC obstructive pulmonary disease, BRONCHIECTASIS, COUGH, NON-smokers, ASPERGILLUS, PULMONARY aspergillosis
Abstract

The article focuses on assessing the prevalence of allergic sensitization to Aspergillus fumigatus (AS) in chronic obstructive pulmonary disease (COPD) patients, comparing smokers and non-smokers. It explores the association between AS and factors like tobacco smoking, biomass fuel exposure, and the prevalence of allergic bronchopulmonary aspergillosis (ABPA), particularly in those who smoke bidis or cigarettes.

Published
2024
Full Text
View/download PDF

38. Population prevalence of aspergillus sensitization and allergic bronchopulmonary aspergillosis in COPD subjects in North India.

Author

Soundappan, Kathirvel, Muthu, Valliappan, Dhooria, Sahajal, Sehgal, Inderpaul Singh, Prasad, Kuruswamy Thurai, Rudramurthy, Shivaprakash Mandya, Chakrabarti, Arunaloke, Aggarwal, Ashutosh N., and Agarwal, Ritesh

Subjects
PULMONARY aspergillosis, CHRONIC obstructive pulmonary disease, ASPERGILLUS fumigatus, ASPERGILLOSIS, LUNGS, EOSINOPHILIA
Abstract

Background: Sensitization to Aspergillus fumigatus (AS) has been recently described in chronic obstructive pulmonary disease (COPD) patients. However, there is no data on the community prevalence of AS in COPD. Objectives: To assess the prevalence of AS among COPD subjects. The secondary objectives were to (1) assess the prevalence of allergic bronchopulmonary aspergillosis (ABPA) in COPD and (2) compare the lung function in COPD subjects with and without AS. Methods: We conducted a cross‐sectional study in rural (29 villages) and urban (20 wards) communities in North India. We identified individuals with respiratory symptoms (IRS) through a house‐to‐house survey using a modified IUATLD questionnaire. We then diagnosed COPD through specialist assessment and spirometry using the GOLD criteria. We assayed A.fumigatus‐specific IgE in COPD subjects. In those with A. fumigatus‐specific IgE ≥0.35 kUA/L (AS), ABPA was diagnosed with raised serum total IgE and raised A.fumigatus‐specific IgG or blood eosinophil count. Results: We found 1315 (8.2%) IRS among 16,071 participants >40 years and diagnosed COPD in 355 (2.2%) subjects. 291 (82.0%) were men and 259 (73.0%) resided in rural areas. The prevalence of AS and ABPA was 17.7% (95% CI, 13.9–21.8) and 6.6% (95% CI, 4.4–8.8). We found a lower percentage predicted FEV1 in COPD subjects with AS than those without (p =.042). Conclusions: We found an 18% community prevalence of AS in COPD subjects in a specific area in North India. Studies from different geographical areas are required to confirm our findings. The impact of AS and ABPA on COPD requires further research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group

Author

Agarwal, Ritesh, primary, Singh Sehgal, Inderpaul, additional, Muthu, Valliappan, additional, Denning, David W, additional, Chakrabarti, Arunaloke, additional, Soundappan, Kathirvel, additional, Garg, Mandeep, additional, Rudramurthy, Shivaprakash M, additional, Dhooria, Sahajal, additional, Armstrong-James, Darius, additional, Asano, Koichiro, additional, Gangneux, Jean-Pierre, additional, Chotirmall, Sanjay H, additional, Salzer, Helmut J.F., additional, Chalmers, James D, additional, Godet, Cendrine, additional, Joest, Marcus, additional, Page, Iain, additional, Nair, Parameswaran, additional, Arjun, p, additional, Dhar, Raja, additional, Ram Jat, Kana, additional, Joe, Geethu, additional, Krishnaswamy, Uma Maheswari, additional, Mathew, Joseph L, additional, Nagarjuna Maturu, Venkata, additional, Mohan, Anant, additional, Nath, Alok, additional, Patel, Dharmesh, additional, Savio, Jayanthi, additional, Saxena, Puneet, additional, Soman, Rajeev, additional, Thangakunam, Balamugesh, additional, Baxter, Caroline G, additional, Bongomin, Felix, additional, Calhoun, William J, additional, Cornely, Oliver A, additional, Douglass, Jo A, additional, Kosmidis, Chris, additional, Meis, Jacques F, additional, Moss, Richard, additional, Pasqualotto, Alessandro C., additional, Seidel, Danila, additional, Sprute, Rosanne, additional, Thurai Prasad, Kuruswamy, additional, and Aggarwal, Ashutosh N, additional

Published
2024
Full Text
View/download PDF

45. Incidence and prevalence of chronic pulmonary aspergillosis in patients with post‐tuberculosis lung abnormality: Results from a community survey in North India

Author

Soundappan, Kathirvel, primary, Sehgal, Inderpaul Singh, additional, Prabhakar, Nidhi, additional, Rana, Samriti, additional, Raju, Rajesh, additional, Dhooria, Sahajal, additional, Prasad, Kuruswamy Thurai, additional, Muthu, Valliappan, additional, Rudramurthy, Shivaprakash M., additional, Chakrabarti, Arunaloke, additional, Garg, Mandeep, additional, and Agarwal, Ritesh, additional

Published
2024
Full Text
View/download PDF

46. Sensitivity and specificity of LDBioAspergillusICT lateral flow assay for diagnosing allergic bronchopulmonary aspergillosis in adult asthmatics

Author

Sehgal, Inderpaul Singh, primary, Muthu, Valliappan, additional, Dhooria, Sahajal, additional, Prasad, Kuruswamy Thurai, additional, Rudramurthy, Shivaprakash M., additional, Aggarwal, Ashutosh Nath, additional, Garg, Mandeep, additional, Gangneux, Jean‐Pierre, additional, Chakrabarti, Arunaloke, additional, and Agarwal, Ritesh, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results